Sick with "shareholder value" : US pharma's financialized business model during the pandemic
William Lazonick and Öner Tulum
| Year of publication: |
2024
|
|---|---|
| Authors: | Lazonick, William ; Tulum, Öner |
| Published in: |
Competition & change : the journal of global business and political economy. - London : Sage Publishing, ISSN 1477-2221, ZDB-ID 2069541-X. - Vol. 28.2024, 2, p. 251-273
|
| Subject: | US pharmaceutical industry | maximizing shareholder value | predatory value extraction | stock buybacks | stock-based executive pay | COVID-19 pandemic | Shareholder Value | Shareholder value | Pharmaindustrie | Pharmaceutical industry | Coronavirus | Geschäftsmodell | Business model | USA | United States | Epidemie | Epidemic | Börsenkurs | Share price | Führungskräfte | Managers | Aktienrückkauf | Share repurchase | Arzneimittel | Pharmaceuticals | Managervergütung | Executive compensation |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1177/10245294231210975 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10014631334